Association of moderately abnormal behavior and administered neuraminidase inhibitors
Tamie Sugawara1, Yasushi Ohkusa1, Kiyosu Taniguchi2
1Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Abstract:
Our earlier study investigated the incidence of severe abnormal behavior associated with neuraminidase inhibitors (NIs), but some studies have specifically examined the association of oseltamivir use and moderately abnormal behavior. Therefore, this study was undertaken to assess associations between moderately abnormal behavior and administered drugs. All cases of patients with influenza who exhibited moderately abnormal behavior were reported to us by physicians of all sentinel clinics and hospitals for influenza throughout Japan. Open Data of the National Database of Electronic Medical Claims include the numbers of patients diagnosed as having influenza who were prescribed NI. Incidence by NI was tested using Fisher's exact test. We received 518 moderately abnormal cases in 5-9-year-olds and 207 moderately abnormal behavior cases in 10-19-year-olds. The incidence among NI ranged from 193 per one million influenza patients in laninamivir among 10-19-year-olds to 1021 for peramivir among 5-9-year-olds. Estimation results revealed the order of risk among NIs as peramivir, oseltamivir, zanamivir and laninamivir in moderate abnormal behavior. Because of data limitations, risk among patients with and without NI cannot be compared.
Insights
This study assessed moderately abnormal behavior in young influenza patients taking neuraminidase inhibitors (NIs). Peramivir and oseltamivir showed a higher incidence of these behaviors compared to zanamivir and laninamivir.
Area of Science:
- Pharmacology
- Neuroscience
- Infectious Diseases
Background:
- Previous research explored severe abnormal behavior linked to neuraminidase inhibitors (NIs).
- Limited studies specifically addressed moderately abnormal behavior associated with oseltamivir use.
Purpose of the Study:
- To investigate the association between moderately abnormal behavior and specific neuraminidase inhibitors (NIs) in influenza patients.
- To compare the incidence of moderately abnormal behavior across different NIs.
Main Methods:
- Data collected from physicians across Japan on influenza patients exhibiting moderately abnormal behavior.
- Utilized Open Data from the National Database of Electronic Medical Claims for NI prescriptions.
- Fisher's exact test was employed to analyze incidence rates by NI.
Main Results:
- 518 cases of moderately abnormal behavior in 5-9-year-olds and 207 in 10-19-year-olds were reported.
- Incidence rates varied significantly among NIs, with peramivir in 5-9-year-olds showing the highest (1021/million).
- Risk order for moderately abnormal behavior was estimated as peramivir > oseltamivir > zanamivir > laninamivir.
Conclusions:
- The study identified differential risks of moderately abnormal behavior among NIs in pediatric influenza patients.
- Peramivir and oseltamivir were associated with a higher incidence of these behaviors.
- Further research is needed to compare risks between NI users and non-users due to data limitations.
